目的 探讨无抽搐电休克治疗精神分裂症激越行为的临床疗效及安全性.方法 将60例伴激越行为的精神分裂症患者按照随机数字表法分为两组,每组30例.对照组口服奥氮平治疗,观察组予以无抽搐电休克治疗,观察2周.于治疗前后采用阳性与阴性症状量表、Cohen-Mansfield激越问卷评定临床疗效,并比较两组不良反应发生率.结果 治疗前两组患者阳性与阴性症状量表、Cohen-Mansfield激越问卷评分比较差异均无统计学意义(P>0.05);治疗2周末,两组均较治疗前显著降低(P<0.01),观察组显著低于对照组(P<0.01).观察组不良反应发生率为6.7%,对照组为16.7%,两组比较差异无统计学意义(P>0.05).结论 无抽搐电休克能显著改善精神分裂症患者的激越症状,临床疗效显著,安全性高.、Objective To explore the efficacy and safety of modified electroconvulsive therapy (MECT) in the treatment of agitation behaviors of schizophrenia.Methods Sixty schizophrenics with agitation behaviors were assigned to two groups of 30 ones each according to random number table.Control group was treated with oral olanzapine and observation with MECT for 2 weeks.Efficacies were assesses with the Positive and Negative Syndrome Scale (PANSS) and Cohen-Mansfield Agitation Inventory (CMAI) before and after treatment and the incidences of adverse reactions compared between two groups.Results There were no significant group differences in before treatment (P>0.05);at the end of the 2nd week the PANSS and CMAI scores of both groups lowered more significantly compared with pretreatment (P<0.01) and those were significantly lower in observation than in control group (P<0.01).The incidence of adverse reactions was respectively 6.7% in observation and 16.7% in control group, which showed no significant group difference (P>0.05).Conclusion MECT could notably improve agitation behaviors of schizophrenia, its efficacy is notable, and safety high.